ECM
TEVA icon

Estabrook Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Estabrook Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,200
Closed -$9.61K – 437
2021
Q4 		$9.61K Buy
+1,200
New +$10.8K ﹤0.01% 334
2016
Q4 		– Sell
-1,400
Closed -$64.4K – 448
2016
Q3 		$64.4K Hold
1,400
– – 0.01% 220
2016
Q2 		$70.3K Hold
1,400
– – 0.01% 205
2016
Q1 		$74.9K Hold
1,400
– – 0.01% 194
2015
Q4 		$91.9K Hold
1,400
– – 0.01% 190
2015
Q3 		$79K Hold
1,400
– – 0.01% 199
2015
Q2 		$82.7K Hold
1,400
– – 0.01% 207
2015
Q1 		$87.2K Hold
1,400
– – 0.01% 215
2014
Q4 		$80.5K Hold
1,400
– – 0.01% 223
2014
Q3 		$75.3K Hold
1,400
– – 0.01% 233
2014
Q2 		$73.4K Sell
1,400
-400
-22% -$20.4K 0.01% 237
2014
Q1 		$95.1K Hold
1,800
– – 0.01% 225
2013
Q4 		$72.1K Sell
1,800
-4,500
-71% -$177K 0.01% 244
2013
Q3 		$238K Sell
6,300
-175
-3% -$6.83K 0.03% 161
2013
Q2 		$254K Buy
+6,475
New +$252K 0.03% 163

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Estabrook Capital Management's TEVA Position: Q1 2022 in Review

Estabrook Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 1,200 shares — an estimated $9.61K sold.

Estabrook Capital Management first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $254K in Q2 2013. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Estabrook Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Estabrook Capital Management sold 1,200 Teva Pharmaceuticals shares in Q1 2022, an estimated $9.61K.
  • Estabrook Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Estabrook Capital Management's Teva Pharmaceuticals position peaked at $254K in Q2 2013.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Estabrook Capital Management's 13F filing for Q1 2022, filed 13 May 2022.